title: Cost Effectiveness of Romiplostim for the Treatment of Immune Thrombocytopenia (Itp) Patients In the Czech Republic.
authors.affiliation: Amgen s. r. o., Praha 1, Czech Republic.
authors.forename: T
authors.initials: T
authors.lastname: Brezina
authors.affiliation: VALUE OUTCOMES, Prague, Czech Republic.
authors.forename: J
authors.initials: J
authors.lastname: Klimes
authors.affiliation: VALUE OUTCOMES, Prague, Czech Republic.
authors.forename: T
authors.initials: T
authors.lastname: Dolezal
authors.affiliation: Amgen s. r. o., Praha 1, Czech Republic.
authors.forename: H
authors.initials: H
authors.lastname: Maskova
authors.affiliation: Amgen (Europe) GmbH, Zug, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Campioni
authors.affiliation: Amgen (Europe) GmbH, Zug, Switzerland.
authors.forename: L
authors.initials: L
authors.lastname: Kutikova